Home > Search Results

Cost-effectiveness: chronic myeloid leukaemia in chronic phase

The cost-effectiveness models reported in the manufacturer submissions were assessed against the NICE reference case and are critically appraised using the framework presented by Phillips et al., who synthesised the literature on evaluating decision-analytic models in health technology assessment to present guidelines for good reporting practice.

Cost-effectiveness: chronic myeloid leukaemia in accelerated phase

As explained earlier (see Chapter 3), we have not produced a de novo model of CML-AP because of the lack of clinical effectiveness data for comparator treatments. As an alternative, in this section, we provide a review, critical appraisal and exploration of the cost-effectiveness analyses contained within the manufacturer submissions made to NICE.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...